To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis
← catalyst calendarNCT06901505 · readout ≤ 12 d
Sponsored by Akebia Therapeutics (industry) · AKBA — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
353actual
Sites
18
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-24 | actual | When the study began enrolling |
| Primary completion | Aug 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Anemia of Chronic Kidney Disease
Interventions
- Drug: Erythropoiesis-Stimulating Agent (ESA)
- Drug: Vadadustat — also filed as Vafseo, AKB-6548
Primary outcome
what the primary-completion date above is the date OFChange in hemoglobin (Hb)
measured Baseline and the mean of Week 20 to 24
Permalink · AKBA's whole pipeline · Catalyst calendar · Every registered study · What changed